Table 1 Characteristics of the study population. Girls offered HPV vaccine during 2009–2014 (n = 177,387)
n (%) | |
|---|---|
HPV vaccine uptake | |
Initiated | 146,403 (82.5) |
Did not initiate | 30,984 (17.5) |
Country backgrounda | |
Norway | 158,738 (89.5) |
Western Europe | 2072 (1.2) |
Central- and Eastern Europe | 3887 (2.2) |
Middle East and North Africa | 3729 (2.1) |
South-Asia | 3355 (1.9) |
East−/South-East Asia | 2236 (1.3) |
Sub-Saharan Africa | 2775 (1.6) |
America and Oceania | 595 (0.3) |
Year of birth (Programme year)b | |
1997 (2009) | 30,209 (17.0) |
1998 (2010) | 29,719 (16.8) |
1999 (2011) | 30,100 (17.0) |
2000 (2012) | 30,098 (17.0) |
2001 (2013) | 28,932 (16.3) |
2002 (2014) | 28,329 (16.0) |
Parental education (years of schooling) | |
Primary school/compulsory level (≤ 10) | 32,865 (18.5) |
Upper secondary level (11–14) | 66,711 (37.6) |
Higher education, undergraduate level (14–17) | 63,003 (35.5) |
Higher education, graduate level (≥ 18) | 14,808 (8.4) |
Household income quintile (NOK) | |
1 (≤ 575,319) | 34,736 (19.6) |
2 (575,320–811,300) | 35,412 (20.0) |
3 (811,301–988,227) | 35,704 (20.1) |
4 (988,228–1,251,798) | 35,778 (20.2) |
5 (≥ 1,251,799) | 35,757 (20.2) |
Number of siblings | |
0 | 8203 (4.6) |
1 | 66,237 (37.3) |
2 | 62,468 (35.2) |
3 | 24,561 (13.9) |
≥ 4 | 15,918 (9.0) |
Maternal age at time of daughter’s birth (years) | |
≤ 25 | 38,939 (22.0) |
26–30 | 64,254 (36.2) |
31–35 | 51,947 (29.3) |
> 35 | 22,247 (12.5) |
Region of residence | |
Oslo | 15,889 (9.0) |
Eastern-Norway | 45,259 (25.5) |
Southern-Norway | 34,892 (20.1) |
Western-Norway | 39,283 (22.2) |
Mid-Norway | 24,948 (14.1) |
Northern-Norway | 17,116 (9.7) |